GeneReach Biotechnology Capital Reinvestment Ratio
GeneReach Biotechnology capital reinvestment ratio. GeneReach Biotechnology (4171) has a Capital Reinvestment Ratio of 1.29x as of June 2026, meaning it reinvests 1% of its operating cash flow (NT$6.28 Million) in capital expenditures (NT$8.13 Million). Check GeneReach Biotechnology cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of GeneReach Biotechnology (2018–2022)
Capital reinvestment ratio of GeneReach Biotechnology from 2018 to 2022. This chart tracks GeneReach Biotechnology's Capital Reinvestment Ratio across 4 annual periods. Also explore 4171 net asset momentum to track the company's year-over-year net asset growth rate.
GeneReach Biotechnology Capital Reinvestment Ratio by Year (2018–2022)
GeneReach Biotechnology capital reinvestment ratio by year from 2018 to 2022. For the full cash flow conversion analysis, see 4171 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.13x | NT$357.63 Million | NT$44.90 Million | ▲ +177.5% |
| 2021 | 0.05x | NT$348.99 Million | NT$15.79 Million | ▼ -88.2% |
| 2020 | 0.38x | NT$169.82 Million | NT$64.87 Million | ▼ -4.9% |
| 2018 | 0.40x | NT$5.74 Million | NT$2.31 Million | — |